HomeTrialNCT06540833
🔬NCT06540833Phase 2RECRUITING

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

Study Summary

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment370 participants
Primary Completion
Lead SponsorIntra-Cellular Therapies, Inc.
Data Retrieved2026-04-11 04:18:13.264777+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.